Boyce Sarah
- SEC CIK
- 0001629383
In the past year, 2 open-market sale filings worth $1.66M and no purchases.
Current role at each company
- RNA Atrium Therapeutics, Inc.Directoras of Sep 22, 2026
- CTNM Contineum Therapeutics, Inc.Directoras of Jun 26, 2026
- Avidity Biosciences, Inc.President and CEOas of Feb 27, 2026
- OABI OmniAb, Inc.Directoras of Jun 21, 2024
- LGND Ligand Pharmaceuticals IncOther: Former Directoras of Nov 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $1.66M
- 2 filings
- Net
- −$1.66M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Boyce Sarah as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
Avidity Biosciences, Inc.
President and CEO21 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2026 (view filing) | Jan 21 | 2 days | Boyce SarahPresident and CEO | SSale | −14.4K | $72.45 | −$1.04M | −5.1%269.0K after | 2 lots10b5-1 |
| Jan 9, 2026 (view filing) | Jan 7 | 2 days | Boyce SarahPresident and CEO | SSale | −8.58K | $72.23 | −$619.4K | −2.9%283.4K after | 10b5-1 |
| Sep 5, 2025 (view filing) | Sep 5 | Same day | Boyce SarahPresident and CEO | SSale | −50.0K | $49.95 | −$2.50M | −14.1%305.9K after | 10b5-1 |
| Aug 29, 2025 (view filing) | Aug 28 | 1 day | Boyce SarahPresident and CEO | SSale | −25.0K | $49.39 | −$1.23M | −7.6%305.9K after | 10b5-1 |
| Mar 21, 2025 (view filing) | Mar 20 | 1 day | Boyce SarahPresident and CEO | SSale | −31.5K | $31.06 | −$979.6K | −9.3%305.9K after | 10b5-1 |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Boyce SarahPresident and CEO | SSale | −10.4K | $28.59 | −$297.3K | −3.0%337.4K after | 2 lots10b5-1 |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Boyce SarahPresident and CEO | SSale | −31.9K | $32.66 | −$1.04M | −10.7%265.3K after | 10b5-1 |
| Sep 23, 2024 (view filing) | Sep 23 | Same day | Boyce SarahPresident and CEO | SSale | −32.9K | $44.00 | −$1.45M | −12.3%234.7K after | 10b5-1 |
| Aug 7, 2024 (view filing) | Aug 6 | 1 day | Boyce SarahPresident and CEO | SSale | −28.0K | $43.35 | −$1.21M | −12.0%205.0K after | 10b5-1 |
| Jul 11, 2024 (view filing) | Jul 9 | 2 days | Boyce SarahPresident and CEO | SSale | −28.0K | $39.93 | −$1.12M | −12.0%205.0K after | 10b5-1 |
OABI OmniAb, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2022 (view filing) | Nov 9-10 | 5 days | Boyce SarahDirector | PPurchase | +36.0K | $2.82 | +$101.3K | New position36.0K after | 2 lots |